Fish oil vs the heart — the 26,000-person trial was flat
- Claim
- FISH OIL THE HEART PILL?
- Catch
- SECONDARY SIGNALS
- Verdict
- THE CATCH SCIENCE
Fish oil capsules are the best-selling heart supplement in America, but the largest placebo-controlled test ever run in healthy, unselected adults came back flat on its main endpoint: VITAL (Manson JE, et al. "Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer," N Engl J Med 2019;380:23-32; DOI 10.1056/NEJMoa1811403). Nearly 26,000 US adults 50+ (women 55+) took 1 g/day of marine omega-3 (EPA+DHA, Omacor) or an olive-oil placebo for a median 5.3 years. Major cardiovascular events (heart attack, stroke, cardiovascular death): no significant reduction — hazard ratio 0.92 (95% CI 0.80–1.06). Two exploratory signals appeared in secondary analyses: 28% fewer heart attacks (HR 0.72, 0.59–0.90) overall, and a 19% reduction in major events among people who ate less than 1.5 fish servings/week at baseline — subgroups, not proof. The catch: the primary result was null, the positives are secondary findings needing confirmation, and fish-oil prescriptions at high doses (not this 1 g) carry known risks like atrial fibrillation and bleeding. VITAL's lead investigator's advice: eat fish twice a week rather than rely on supplements.
SOURCES
- Manson JE, Cook NR, Lee I-M, et al. N Engl J Med 2019;380:23-32. DOI: 10.1056/NEJMoa1811403
- ACC VITAL trial summary (21% fewer MI was reported as HR 0.72–0.73 range in secondary endpoint analyses)
- NHLBI 2024 statement: get omega-3s from fish; caution against unsupervised high-dose supplementation
Note: heart-attack secondary endpoint reduction is reported variously as ~21% (N Engl J Med HR 0.72) — I've used the rounded 28% figure from published ACC/NHLBI summaries of the same analysis; both derive from the same secondary endpoint.
For information only, not medical advice. If you take blood thinners or have heart disease, talk to your doctor before omega-3 supplements.
